Home › Waldenstrom Macroglobulinemia
Pag-aaral pangklinika para sa Waldenstrom Macroglobulinemia na nagre-recruit sa U.S.
29 pag-aaral para sa Waldenstrom Macroglobulinemia ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Durham, NC10 pag-aaral
- Boston, MA9 pag-aaral
- Denver, CO7 pag-aaral
- Edison, NJ6 pag-aaral
- New York City, NY6 pag-aaral
- Dallas, TX6 pag-aaral
- Houston, TX6 pag-aaral
- Rochester, MN5 pag-aaral
- Seattle, WA5 pag-aaral
- Milwaukee, WI5 pag-aaral
- Queens, NY4 pag-aaral
- Columbus, OH4 pag-aaral
- Baldwin Park, CA4 pag-aaral
- Chicago, IL4 pag-aaral
- Washington, DC4 pag-aaral
- Jacksonville, FL3 pag-aaral
- Miami, FL3 pag-aaral
- Richmond, VA3 pag-aaral
- Portland, OR3 pag-aaral
- Cincinnati, OH3 pag-aaral
- Philadelphia, PA3 pag-aaral
- Salt Lake City, UT3 pag-aaral
- Nashville, TN3 pag-aaral
- Cleveland, OH3 pag-aaral
Ayos sa estado
- Arizona4 pag-aaral
- California11 pag-aaral
- Colorado8 pag-aaral
- Florida7 pag-aaral
- Georgia3 pag-aaral
- Illinois5 pag-aaral
- Iowa3 pag-aaral
- Maryland5 pag-aaral
- Massachusetts11 pag-aaral
- Michigan5 pag-aaral
- Minnesota5 pag-aaral
- New Jersey7 pag-aaral
- New York8 pag-aaral
- North Carolina12 pag-aaral
- Ohio8 pag-aaral
- Oregon3 pag-aaral
- Pennsylvania3 pag-aaral
- Tennessee3 pag-aaral
- Texas11 pag-aaral
- Utah3 pag-aaral
- Virginia3 pag-aaral
- Washington7 pag-aaral
- Wisconsin6 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT07231952A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05006716Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 110 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT00923507Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT04840602Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT04728893A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07101328Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 1, 2026 · NCT06561347A Study of ARC-02 in B-cell NHL
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT07691606AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT06340737Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT07426484Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 7, 2026 · NCT05640102A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT06708897A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 30, 2026 · NCT07424833A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT05131022Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 1, 2026 · NCT06860880Registry of Older Patients With Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 65 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT01137825Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update May 7, 2026 · NCT02269592SynKIR-310 for Relapsed/Refractory B-NHL
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 14, 2026 · NCT06544265A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 20, 2026 · NCT04830137Epcoritamab in Previously Treated WM
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT06510491Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Peb 27, 2026 · NCT06151730Study of SGR-1505 in Mature B-Cell Neoplasms
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT05544019Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT04775745AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 10, 2025 · NCT05602363A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 5, 2025 · NCT06986174Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.